The primary goal of therapy for chronic hepatitis B (CHB) is to prevent liver disease progression. Hepatitis B surface antigen (HBsAg) seroclearance or seroconversion is regarded as an optimal endpoint to discontinue treatment. However. HBsAg seroclearance occurs very rarely with nucleos(t)ide analog (NUC) treatment. https://ashleyshomestores.shop/product-category/occasional-table-set-set-of-3/